CellMosaic offers bioconjugation research and development services for biopharmaceutical companies devoted to antisense and siRNA-based therapeutics.
Some of the obstacles to developing oligonucleotide analogs and siRNA-based therapeutics include limited cellular uptake, poor in vivo pharmacokinetic properties, and a lack of specificity for the target tissues/cells. New studies have shown that chemically conjugated oligonucleotide analogs and siRNAs with bioactive molecules, lipids, and polymers can overcome some of these limitations.
We prepare oligo-based conjugates using a unique conjugation strategy developed at CellMosaic. PEG or other classical polymers can be conjugated anywhere on the oligo (3', 5', or via a modified base) in either the solid phase or post-synthesis solution phase. Usually a single pure conjugate can be obtained. The advantages of our oligo conjugation strategy are:
Case Studies: